Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

6-MAPB

This article is a stubmissing:
Subjective Effects
Interactions
Tolerance
Legality
6-MAPB molecule structure6-MAPB molecule structure
Open in Piru
Chemical Class
Benzofuran

6-MAPB is a benzofuran1 structurally related to 6-APB1 and MDMA. Sources also classify it as an empathogen, stimulant, and psychedelic. It was first encountered as a novel designer drug in 2013 and described in scientific literature in 2014. Its reported relationship to other benzofurans distinguishes it within this group, although its broader psychoactive classification is uncertain.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~10 mg
Light10-20 mg
Moderate20-40 mg
Strong40-100 mg
Heavy100+ mg

Subjective Effects

Subjective Effects not written up yet

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Morr(MO)
pink2 → green1
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

6-MAPB is a serotonin releasing agent2 and a potent agonist at serotonin 5-HT1B receptors. This distinguishes it pharmacologically from MDMA, which is described here without the same 5-HT1B agonist activity.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Addiction & Dependence

Psychological

Moderate

Classified as habit-forming. As an empathogen-stimulant, it may carry moderate psychological addiction potential similar to related compounds.

Psychosis Risk

Visual and auditory hallucinations have been reported as negative effects, along with aggressiveness and moodiness.

History & Culture

6-MAPB was first encountered as a novel designer drug in 2013 and was described in scientific literature in 2014. It was not known to have been widely sold, but it was detected in analytical samples from people hospitalized after using combinations that included other benzofuran derivatives. The United Kingdom banned 6-MAPB in June 2013 along with nine related compounds considered likely to produce similar effects.

Legality

Legality not written up yet

References

Citations

  1. Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology (2019). https://doi.org/10.1007/s00213-019-05133-612
  2. The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats. Psychopharmacology (Berl.) / PubMed Central (2020). https://doi.org/10.1007/s00213-020-05648-z12

Further Reading

  1. Shimshoni et al. 2016 - Neurochemical binding profiles of novel indole and benzofuran MDMA analogues
  2. Welter-Luedeke & Maurer 2016 - New Psychoactive Substances

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 6-MAPB article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.